慢性硬膜下血肿钻孔术后辅助口服氨甲环酸与再手术:基于全国住院数据库的倾向评分匹配分析
基于日本全国住院数据库2010年7月1日至2019年3月31日149543例慢性硬膜下血肿钻孔手术患者,其中7366例(4.9%)为氨甲环酸使用者。倾向评分匹配后6564对分析显示,氨甲环酸组再手术率1.9% vs 非使用者6.1%(p<0.001),风险差-4.1%(95%CI -4.8%至-3.4%),复合不良事件无显著差异(0.6% vs 0.5%,p=0.817)。
要点
- 慢性硬膜下血肿钻孔术后辅助口服氨甲环酸与再手术率降低相关(1.9% vs 6.1%,p<0.001)。
- 氨甲环酸组复合不良事件发生率0.6% vs 非使用者0.5%,无显著差异(p=0.817)。
- 氨甲环酸组总住院费用显著低于非使用者(5229美元 vs 5344美元,p<0.001)。
核心结论
- 基于全国住院数据库的观察性研究提示,慢性硬膜下血肿钻孔术后辅助使用氨甲环酸与再手术率降低相关。
研究设计与样本
- 观察性研究,使用日本诊断程序组合住院数据库(全国住院数据库),纳入2010年7月1日至2019年3月31日因慢性硬膜下血肿入院并在入院2天内行钻孔手术的患者。
- 共149543例慢性硬膜下血肿患者,来自1100家医院,其中7366例(4.9%)为术后2天内开始口服氨甲环酸的使用者。
- 采用1:1倾向评分匹配比较氨甲环酸使用者与非使用者的结局,共产生6564对匹配患者,基线特征高度均衡;并使用工具变量分析评估稳健性。
主要发现
- 主要结局为术后1年内再手术,氨甲环酸使用者再手术率1.9% vs 非使用者6.1%(p<0.001),风险差-4.1%(95%CI -4.8%至-3.4%)。
- 复合不良事件发生率氨甲环酸组0.6% vs 非使用者0.5%,无显著差异(p=0.817)。
- 总住院费用氨甲环酸组5229美元 vs 非使用者5344美元,氨甲环酸组显著更低(p<0.001)。
- 工具变量分析结果与倾向评分匹配分析结果一致。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Adjuvant medical treatment to reduce the recurrence rate after burr hole surgery for chronic subdural hematoma (CSDH) has not yet been established. This study aimed to investigate the association between tranexamic acid (TXA) use after burr hole surgery and the reoperation rate in patients with CSDH. METHODS: This observational study used the Japanese Diagnostic Procedure Combination inpatient database, a nationwide inpatient database in Japan, from July 1, 2010, to March 31, 2019. The authors identified patients who were hospitalized for CSDH and underwent burr hole surgery within 2 days of admission. The primary outcome measure was reoperation within 1 year after surgery. One-to-one propensity score-matched analysis was performed to compare the outcomes between patients who started oral TXA within 2 days after surgery (TXA users) and those who did not (TXA nonusers). Robustness of the analyses was assessed using the instrumental variable analysis. RESULTS: Of the 149,543 patients with CSDH treated at 1100 hospitals, 7366 (4.9%) were TXA users. Propensity score matching created 6564 matched pairs with highly balanced baseline characteristics. The reoperation rate was significantly lower in TXA users than in nonusers (1.9% vs 6.1%, p < 0.001) with a risk difference of -4.1% (95% CI -4.8% to -3.4%). There was no significant difference in composite adverse events (0.6% vs 0.5%, p = 0.817). Total hospitalization costs were also significantly lower in TXA users than in nonusers ($5229 vs $5344 [USD], p < 0.001). The results of the instrumental variable analysis were consistent with those of the propensity score-matched analysis. CONCLUSIONS: Findings of this study, using a nationwide inpatient database, suggest that adjuvant TXA use after burr hole surgery was associated with a reduced reoperation rate in patients with CSDH.
引用
- Shibahashi K, Ohbe H, Yasunaga H, et al. Adjuvant oral tranexamic acid and reoperation after burr hole surgery in patients with chronic subdural hematoma: propensity score-matched analysis using a nationwide inpatient database. J Neurosurg. 2022. PMID: 35901677. doi:10.3171/2022.5.JNS22664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。